{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:40Z","timestamp":1792782700227,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82400245"],"award-info":[{"award-number":["82400245"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20230807110405012"],"award-info":[{"award-number":["JCYJ20230807110405012"]}]},{"name":"Sanming Project of Medicine in Shenzhen","award":["SZSM202411022"],"award-info":[{"award-number":["SZSM202411022"]}]},{"name":"National Key R&D program of China","award":["2023YFA1800100"],"award-info":[{"award-number":["2023YFA1800100"]}]},{"name":"Innovative Clinical Technique of Guangzhou","award":["No. 2023C-GX01"],"award-info":[{"award-number":["No. 2023C-GX01"]}]},{"name":"2019 Annual Research Project of the China Marrow Donor Program","award":["No. CMDO201902"],"award-info":[{"award-number":["No. CMDO201902"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IST+EPAG) is the preferred first-line treatment for severe aplastic anemia (SAA) patients over 40 years. However, direct comparison between IST+EPAG and upfront haploidentical hematopoietic stem cell transplantation (HID-HSCT) in this population remains limited. We retrospectively analyzed 123 newly diagnosed SAA patients aged 40\u201365 who received first-line HID-HSCT (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200967) or IST+EPAG (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200956) between 2016 and 2024. Hematological response, survival, and safety were compared. The HID-HSCT group demonstrated superior complete response (CR) rates at 3 months (17.9% vs. 5.4%), 6 months (44.8% vs. 17.9%), and 12 months (64.2% vs. 33.9%) (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). The 3-year overall survival (OS) was comparable between the HID-HSCT and IST+EPAG groups (78.0% vs. 80.3%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.662), and a landmark analysis conditional on survival to 6 months confirmed comparable subsequent 3-year OS (92.2% vs. 88.9%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.616). Meanwhile, the 3-year failure-free survival (FFS) was significantly higher in the HID-HSCT group among patients aged 40\u201349 (82.9% vs. 60.1%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.045), whereas no difference was observed in those aged 50\u201365 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.984). HID-HSCT may offer more durable benefits in selected SAA patients aged 40\u201349, while its advantage over IST+EPAG is not evident in patients aged 50\u201365.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07289-2","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:44:52Z","timestamp":1790653492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40\u201365: a multicenter retrospective study"],"prefix":"10.1007","volume":"105","author":[{"given":"Xiaohui","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-4901","authenticated-orcid":false,"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"17","key":"7289_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS (2018) Aplastic Anemia[J]. N Engl J Med 379(17):1643\u20131656","journal-title":"N Engl J Med"},{"issue":"1","key":"7289_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R De Peffault","year":"2022","unstructured":"De Peffault R, Kulasekararaj A, Iacobelli S et al (2022) Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia[J]. N Engl J Med 386(1):11\u201323","journal-title":"N Engl J Med"},{"issue":"3","key":"7289_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline[J]. Br J Haematol 204(3):784\u2013804","journal-title":"Br J Haematol"},{"issue":"15","key":"7289_CR4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/bloodadvances.2018021162","volume":"2","author":"GE Georges","year":"2018","unstructured":"Georges GE, Doney K, Storb R (2018) Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment[J]. Blood Adv 2(15):2020\u20132028","journal-title":"Blood Adv"},{"issue":"3","key":"7289_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.bbmt.2018.08.029","volume":"25","author":"C Rice","year":"2019","unstructured":"Rice C, Eikema D-J, Marsh JCW et al (2019) Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia[J]. Biol Blood Marrow Transplant 25(3):488\u2013495","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"7289_CR6","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1038\/s41375-020-0933-7","volume":"34","author":"L Liu","year":"2020","unstructured":"Liu L, Zhang Y, Jiao W et al (2020) Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia[J]. Leukemia 34(12):3359\u20133369","journal-title":"Leukemia"},{"issue":"6","key":"7289_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12185-025-03940-2","volume":"121","author":"R Yamamoto","year":"2025","unstructured":"Yamamoto R, Hiramoto N, Nagai Y et al (2025) Iron deficiency anemia following long-term eltrombopag treatment for aplastic anemia: a single-institution experience[J]. Int J Hematol 121(6):767\u2013773","journal-title":"Int J Hematol"},{"issue":"9","key":"7289_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jtct.2022.05.027","volume":"28","author":"L-F Huang","year":"2022","unstructured":"Huang L-F, Li L, Jia J-S et al (2022) Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?[J]. Transplantation Cell Therapy 28(9):586.e581\u2013586.e587","journal-title":"Transplantation Cell Therapy"},{"issue":"16","key":"7289_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T et al (2017) Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia[J]. N Engl J Med 376(16):1540\u20131550","journal-title":"N Engl J Med"},{"key":"7289_CR10","doi-asserted-by":"publisher","first-page":"614965","DOI":"10.3389\/fonc.2021.614965","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang Y, Ji J, Tang Z et al (2021) Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review[J]. Front Oncol 11:614965","journal-title":"Front Oncol"},{"issue":"5","key":"7289_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.bbmt.2019.01.017","volume":"25","author":"S Yang","year":"2019","unstructured":"Yang S, Yuan X, Ma R et al (2019) Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor[J]. Biol Blood Marrow Transpl 25(5):975\u2013980","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"7289_CR12","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A (2017) How I treat acquired aplastic anemia[J]. Blood 129(11):1428\u20131436","journal-title":"Blood"},{"issue":"2","key":"7289_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/bmt.2012.224","volume":"48","author":"A Tichelli","year":"2013","unstructured":"Tichelli A, Marsh JC (2013) Treatment of aplastic anaemia in elderly patients aged\u2009>\u200960 years[J]. Bone Marrow Transpl 48(2):180\u2013182","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"7289_CR14","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.bbmt.2018.05.015","volume":"24","author":"Y Lu","year":"2018","unstructured":"Lu Y, Sun RJ, Zhao YL et al (2018) Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia[J]. Biol Blood Marrow Transpl 24(9):1881\u20131887","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"7289_CR15","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.3324\/haematol.2022.280758","volume":"107","author":"ZL Xu","year":"2022","unstructured":"Xu ZL, Xu LP, Wu DP et al (2022) Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study[J]. Haematologica 107(12):2918\u20132927","journal-title":"Haematologica"},{"issue":"9","key":"7289_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.scib.2022.01.024","volume":"67","author":"LP Xu","year":"2022","unstructured":"Xu LP, Xu ZL, Wang SQ et al (2022) Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: a multicenter prospective study[J]. Sci Bull (Beijing) 67(9):963\u2013970","journal-title":"Sci Bull (Beijing)"},{"issue":"12","key":"7289_CR17","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","volume":"56","author":"LP Xu","year":"2021","unstructured":"Xu LP, Lu PH, Wu DP et al (2021) Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group[J]. Bone Marrow Transpl 56(12):2940\u20132947","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"7289_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41409-020-0820-x","volume":"55","author":"SH Shin","year":"2020","unstructured":"Shin SH, Park SS, Yoon JH et al (2020) Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia[J]. Bone Marrow Transpl 55(8):1570\u20131579","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"7289_CR19","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1182\/bloodadvances.2019000480","volume":"3","author":"VS Sheth","year":"2019","unstructured":"Sheth VS, Potter V, Gandhi SA et al (2019) Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years[J]. Blood Adv 3(20):3070\u20133079","journal-title":"Blood Adv"},{"issue":"3","key":"7289_CR20","doi-asserted-by":"publisher","first-page":"e13810","DOI":"10.1111\/ctr.13810","volume":"34","author":"YY Zhang","year":"2020","unstructured":"Zhang YY, Mo WJ, Zuo YY et al (2020) Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study[J]. Clin Transpl 34(3):e13810","journal-title":"Clin Transpl"},{"issue":"10","key":"7289_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41409-024-02377-1","volume":"59","author":"L Liu","year":"2024","unstructured":"Liu L, Han B, Zhang Y et al (2024) First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study[J]. Bone Marrow Transplant 59(10):1449\u20131457","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"7289_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-024-01021-x","volume":"14","author":"L Wu","year":"2024","unstructured":"Wu L, Liu L, Zhao X et al (2024) Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia[J]. Blood Cancer J 14(1):37","journal-title":"Blood Cancer J"},{"issue":"8","key":"7289_CR23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.bbmt.2019.03.020","volume":"25","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wu L, Mo W et al (2019) Comparable Outcomes of First-Line Hematopoietic Stem Cell Transplantation from Unrelated and Matched Sibling Donors in Adult Patients with Aplastic Anemia: A Retrospective Single-Center Study[J]. Biol Blood Marrow Transpl 25(8):1567\u20131575","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"7289_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report[J]. Biol Blood Marrow Transpl 11(12):945\u2013956","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"7289_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","volume":"29","author":"S Jodele","year":"2015","unstructured":"Jodele S, Laskin BL, Dandoy CE et al (2015) A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury[J]. Blood Rev 29(3):191\u2013204","journal-title":"Blood Rev"},{"issue":"8","key":"7289_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41409-018-0410-3","volume":"54","author":"ZL Xu","year":"2019","unstructured":"Xu ZL, Zhou M, Jia JS et al (2019) Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia[J]. Bone Marrow Transpl 54(8):1319\u20131326","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"7289_CR27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3324\/haematol.2023.284581","volume":"109","author":"Z-L Xu","year":"2024","unstructured":"Xu Z-L, Xu L-P, Zhang Y-C et al (2024) The outcome and predictive model of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia from the Chinese Blood and Marrow Transplant Registry Group[J]. Haematol 109(6):2000\u20132004","journal-title":"Haematol"},{"issue":"8","key":"7289_CR28","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","volume":"4","author":"AE Dezern","year":"2020","unstructured":"Dezern AE, Zahurak ML, Symons HJ et al (2020) Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide[J]. Blood Adv 4(8):1770\u20131779","journal-title":"Blood Adv"},{"issue":"25","key":"7289_CR29","first-page":"3031","volume":"141","author":"AE Dezern","year":"2023","unstructured":"Dezern AE, Zahurak M, Symons HJ et al (2023) Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia[J]. Blood 141(25):3031\u20133038","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07289-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07289-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07289-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:02:57Z","timestamp":1792530177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07289-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7289"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07289-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"468"}}